Celgene Corporation (NASDAQ:CELG) was the target of some unusual options trading activity on Thursday. Stock investors bought 23,441 call options on the company. This is an increase of approximately 264% compared to the average volume of 6,440 call options.
Shares of Celgene Corporation (NASDAQ CELG) opened at 139.21 on Friday. The company has a market capitalization of $108.91 billion, a P/E ratio of 43.11 and a beta of 1.88. The company has a 50-day moving average of $139.31 and a 200 day moving average of $129.53. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $147.17.
Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the prior year, the firm earned $1.44 EPS. The firm’s quarterly revenue was up 18.7% compared to the same quarter last year. Analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.
A number of equities research analysts recently weighed in on CELG shares. BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and raised their price target for the company from $96.93 to $131.70 in a report on Friday, June 30th. Leerink Swann reaffirmed an “outperform” rating and set a $160.00 price target (up from $150.00) on shares of Celgene Corporation in a report on Friday, July 28th. Argus raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and raised their price target for the company from $96.93 to $160.00 in a report on Monday, July 31st. Credit Suisse Group set a $148.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. Finally, Stifel Nicolaus started coverage on shares of Celgene Corporation in a report on Friday, July 28th. They set a “buy” rating and a $155.00 price target for the company. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and twenty-two have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $150.60.
In related news, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the sale, the director now directly owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. In the last three months, insiders sold 46,233 shares of company stock worth $6,268,259. Insiders own 0.95% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Beacon Financial Group bought a new stake in shares of Celgene Corporation in the 3rd quarter worth about $351,000. Centre Asset Management LLC bought a new stake in shares of Celgene Corporation in the 3rd quarter worth about $5,878,000. Neville Rodie & Shaw Inc. grew its holdings in shares of Celgene Corporation by 4.7% in the 3rd quarter. Neville Rodie & Shaw Inc. now owns 70,468 shares of the biopharmaceutical company’s stock worth $10,276,000 after purchasing an additional 3,150 shares during the last quarter. Eqis Capital Management Inc. grew its holdings in shares of Celgene Corporation by 16.5% in the 3rd quarter. Eqis Capital Management Inc. now owns 40,165 shares of the biopharmaceutical company’s stock worth $5,857,000 after purchasing an additional 5,685 shares during the last quarter. Finally, Park National Corp OH grew its holdings in shares of Celgene Corporation by 11.5% in the 3rd quarter. Park National Corp OH now owns 4,125 shares of the biopharmaceutical company’s stock worth $601,000 after purchasing an additional 426 shares during the last quarter. 79.36% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Celgene Corporation Sees Unusually High Options Volume (CELG)” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://transcriptdaily.com/2017/10/08/celgene-corporation-sees-unusually-high-options-volume-celg.html.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.